Login to Your Account

Sage shares shine as '547 shows early potential against postpartum depression

By Michael Fitzhugh
Staff Writer

Tuesday, June 9, 2015

Sage Therapeutics Inc. shares rose 15.4 percent on Tuesday after hitting a 52-week high on news that the company is accelerating plans to begin testing its most advanced compound, SAGE-547, in a new trial for the treatment of postpartum depression before the end of this year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription